Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Masoud Toloue will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 12, 2023, at 12 p.m. PST. The presentation will be accessible to attendees and the public via a live audio webcast. Quanterix will also hold one-on-one meetings with institutional investors during the event. Replays of the webcast will be available for a limited time afterward. Quanterix specializes in ultrasensitive biomarker detection, enabling significant advancements in various disease research.
Quanterix Corporation (NASDAQ: QTRX) announced the role of its ultrasensitive Simoa technology in advancing clinical trials for Alzheimer’s disease (AD), presented at the 15th Clinical Trials on Alzheimer's Disease conference in San Francisco. Eisai and Biogen showcased Phase 3 trial results for lecanemab, highlighting biomarker engagement. Additional data from Eli Lilly and Janssen emphasized plasma biomarker utility. Quanterix aims to support future AD therapeutic trials with innovative testing tools, including FDA-designated Breakthrough Devices expected in 2023.
Quanterix Corporation (NASDAQ: QTRX) will participate in the 15th Clinical Trials on Alzheimer's Disease (CTAD) from November 29 to December 2, 2022, in San Francisco. CEO Masoud Toloue is set to present on the advantages of blood-based biomarkers such as pTau-181 and pTau-217 over traditional PET scans for clinical trial efficiency and patient monitoring. These biomarkers have shown promise in Phase III trials, facilitating the design of effective Alzheimer’s disease treatments. The conference aims to accelerate collaboration among leaders in Alzheimer’s research.
Quanterix Corporation (NASDAQ: QTRX) announced that President and CEO Masoud Toloue and CFO Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, at 4:30 p.m. EST in Boston, MA. They will engage in one-on-one and group meetings with institutional investors on the same day. A live webcast of the presentation will be available on Quanterix's Investor website, with replays accessible for 90 days. Quanterix specializes in ultrasensitive biomarker detection aimed at advancing research in various medical fields.
Quanterix Corporation (NASDAQ: QTRX) reported flat revenue of $26.6M for Q3 2022 compared to Q3 2021, up 13% from Q2 2022. Pro-forma gross margin was 35%, down 1470 bps year-over-year but up 670 bps quarter-over-quarter. The company is progressing in the Bio-Hermes trial and received funding from the Alzheimer’s Drug Discovery Foundation to advance Alzheimer's diagnostic tests. However, the restructuring has incurred significant charges, including $8.2M in goodwill impairment. Q3 net loss reached $35.1M, a substantial increase from $15.7M in Q3 2021.
Quanterix Corporation (NASDAQ: QTRX) announced it will hold a conference call on November 8, 2022, at 4:30 PM ET, to discuss its third quarter 2022 financial results. The call will feature President and CEO Masoud Toloue and CFO Michael Doyle. A press release detailing the earnings will be distributed before the call and available on the company’s website.
Quanterix specializes in ultrasensitive biomarker detection, providing significant advancements in various medical fields.
Quanterix Corporation (NASDAQ: QTRX) announces the resignation of Executive Chairman E. Kevin Hrusovsky, who has led the company since June 2014. Martin D. Madaus, previously serving as Executive Chairman and CEO, is appointed as the new Chairman of the Board. Hrusovsky, who played a pivotal role in Quanterix's growth into a leading biomarker detection firm, emphasized the need for board evolution to support future growth. The transition follows a leadership succession plan, with an optimistic outlook on the company's future developments and market position.
Quanterix Corporation (NASDAQ: QTRX) reported a Q2 2022 total revenue of $23.5M, down 7.4% from $25.4M in Q2 2021. Product revenue fell by 20.8% to $14.8M, while service and other revenue increased 51.3% to $8.5M. The gross margin declined to 37.1% from 54.7%, primarily due to assay quality challenges. The company is implementing a strategic restructuring plan, including a $10M charge and a reduction in workforce by 130 employees, aiming for $25M in annual savings. FY2022 revenue is expected to remain flat with a plan to return to double-digit growth by 2024.
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Masoud Toloue will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:30 p.m. ET in Boston, MA. He will also hold one-on-one and group meetings with institutional investors. A live webcast of the presentation will be available on the Quanterix website, with replays accessible for 90 days post-conference. Quanterix focuses on digitizing biomarker analysis to enhance disease detection and treatment across various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) will host a conference call on August 8, 2022, at 4:30 PM ET to discuss its Q2 2022 financial results. The company will release its earnings report prior to the call, accessible on its website. This call will be led by President and CEO Masoud Toloue and CFO Michael Doyle. Quanterix focuses on ultrasensitive biomarker detection to advance precision health, impacting various therapeutic areas like oncology and neurology. More information is available at www.quanterix.com.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?
What is the Simoa Accelerator Laboratory?
